Ticker Symbol: TOS/TSX
Shares Outstanding: 47,863,402
QUEBEC CITY, Dec. 5 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS)
announces the sale of its 23rd 125L Ozone Sterilizer to date, this time to the
flagship hospital of a substantial IDN (Integrated Delivery Network) located
in a major city in the Mountain Time zone, in the US.
"This hospital system decided to exchange a recently acquired
high-capacity sterilizer from a competitor with the objective of significantly
lowering cost and achieving higher reliability while maintaining their
throughput", said Ann Hewitt, VP Sales & Marketing for TSO3 Inc. "Their
research into alternative options convinced them that they would achieve all
of their goals by replacing their current sterilizer with the newest
technology on the market, ozone."
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology whit high commercial potential. The Company's first product, the
125L Ozone Sterilizer, is designed for sterile processing centers in the
In contrast to other methods used, the ozone sterilization process
developed and patented by TSO3 meets all standards required by the evolution
in sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The 125L Ozone Sterilizer is cleared for commercialization by the US Food
and Drug Administration and by Health Canada. TSO3 is in commercialization
phase for this first product since 2006.
TSO3 currently has more than 72 employees, about half of whom work in the
sales and marketing team.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Caroline Côté, Director, Corporate
Communications & IR, (418) 651-0003, Ext. 237, firstname.lastname@example.org; Source: TSO3